CMPS vs. ANAB, STOK, AVBP, ABUS, ATXS, PHAT, ALT, OCS, KRRO, and CALT
Should you be buying COMPASS Pathways stock or one of its competitors? The main competitors of COMPASS Pathways include AnaptysBio (ANAB), Stoke Therapeutics (STOK), ArriVent BioPharma (AVBP), Arbutus Biopharma (ABUS), Astria Therapeutics (ATXS), Phathom Pharmaceuticals (PHAT), Altimmune (ALT), Oculis (OCS), Korro Bio (KRRO), and Calliditas Therapeutics AB (publ) (CALT). These companies are all part of the "pharmaceutical preparations" industry.
COMPASS Pathways (NASDAQ:CMPS) and AnaptysBio (NASDAQ:ANAB) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, earnings, media sentiment, valuation, risk, community ranking and dividends.
COMPASS Pathways has higher earnings, but lower revenue than AnaptysBio. AnaptysBio is trading at a lower price-to-earnings ratio than COMPASS Pathways, indicating that it is currently the more affordable of the two stocks.
In the previous week, AnaptysBio had 2 more articles in the media than COMPASS Pathways. MarketBeat recorded 3 mentions for AnaptysBio and 1 mentions for COMPASS Pathways. AnaptysBio's average media sentiment score of 0.00 beat COMPASS Pathways' score of -1.00 indicating that AnaptysBio is being referred to more favorably in the news media.
COMPASS Pathways has a beta of 2.48, indicating that its stock price is 148% more volatile than the S&P 500. Comparatively, AnaptysBio has a beta of -0.3, indicating that its stock price is 130% less volatile than the S&P 500.
COMPASS Pathways has a net margin of 0.00% compared to AnaptysBio's net margin of -953.66%. COMPASS Pathways' return on equity of -58.72% beat AnaptysBio's return on equity.
AnaptysBio received 302 more outperform votes than COMPASS Pathways when rated by MarketBeat users. However, 76.19% of users gave COMPASS Pathways an outperform vote while only 65.54% of users gave AnaptysBio an outperform vote.
46.2% of COMPASS Pathways shares are held by institutional investors. 4.3% of COMPASS Pathways shares are held by insiders. Comparatively, 35.5% of AnaptysBio shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
COMPASS Pathways currently has a consensus target price of $47.40, suggesting a potential upside of 496.98%. AnaptysBio has a consensus target price of $46.22, suggesting a potential upside of 120.11%. Given COMPASS Pathways' stronger consensus rating and higher possible upside, equities research analysts plainly believe COMPASS Pathways is more favorable than AnaptysBio.
Summary
COMPASS Pathways beats AnaptysBio on 10 of the 17 factors compared between the two stocks.
Get COMPASS Pathways News Delivered to You Automatically
Sign up to receive the latest news and ratings for CMPS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CMPS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
COMPASS Pathways Competitors List
Related Companies and Tools
